Abstract
Prescription icosapent ethyl (IPE) is converted to eicosapentaenoic acid (EPA), an omega-3 fatty acid (O3FA). In the REDUCE-IT trial, EPA significantly reduced clinical events in high-risk patients with diabetes and other risk factors or cardiovascular disease. Previous studies showed that EPA reduces oxidation of ApoB-containing particles in patients with hypertriglyceridemia, thereby potentially improving LDL clearance and reducing plaque progression. The antioxidant benefits of EPA may extend to ApoA-containing particles like HDL, thereby preserving certain atheroprotective functions, in a manner that is enhanced with a statin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
